MeSH Review:
Clinical Trials, Phase I
- Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen. Baldew, G.S., McVie, J.G., van der Valk, M.A., Los, G., de Goeij, J.J., Vermeulen, N.P. Cancer Res. (1990)
- Potentiation of murine MCa-4 carcinoma radioresponse by 9-amino-20(S)-camptothecin. Kirichenko, A.V., Rich, T.A., Newman, R.A., Travis, E.L. Cancer Res. (1997)
- Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia. Venner, P.M., Glazer, R.I., Blatt, J., Sallan, S., Rivera, G., Holcenberg, J.S., Lipton, J., Murphy, S.B., Poplack, D.G. Cancer Res. (1981)
- Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications. Hartman, N.R., Yarchoan, R., Pluda, J.M., Thomas, R.V., Wyvill, K.M., Flora, K.P., Broder, S., Johns, D.G. Clin. Pharmacol. Ther. (1991)
- 3'-Deoxythymidin-2'-ene permeation of human lymphocyte H9 cells by nonfacilitated diffusion. August, E.M., Birks, E.M., Prusoff, W.H. Mol. Pharmacol. (1991)
- Vanoxerine National Institute on Drug Abuse. Preti, A. Current opinion in investigational drugs (London, England : 2000) (2000)
- Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. Friedman, H.S., Dolan, M.E., Moschel, R.C., Pegg, A.E., Felker, G.M., Rich, J., Bigner, D.D., Schold, S.C. J. Natl. Cancer Inst. (1992)
- Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Richon, V.M., Sandhoff, T.W., Rifkind, R.A., Marks, P.A. Proc. Natl. Acad. Sci. U.S.A. (2000)
- New approach for inhibiting Rev function and HIV-1 production using the influenza virus NS1 protein. Qian, X.Y., Chen, Z.Y., Zhang, J., Rabson, A.B., Krug, R.M. Proc. Natl. Acad. Sci. U.S.A. (1996)
- Somatic gene therapy for cystic fibrosis. O'Neal, W.K., Beaudet, A.L. Hum. Mol. Genet. (1994)
- Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. Nielsen, T.O., Andrews, H.N., Cheang, M., Kucab, J.E., Hsu, F.D., Ragaz, J., Gilks, C.B., Makretsov, N., Bajdik, C.D., Brookes, C., Neckers, L.M., Evdokimova, V., Huntsman, D.G., Dunn, S.E. Cancer Res. (2004)
- A comparison of the biological and biochemical properties of 1-(4-amino-2-methylpyrimidin-5-yl)methyl-3-(2-chloroethyl)-3-nitrosourea and 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose. Nagourney, R.A., Fox, P., Schein, P.S. Cancer Res. (1978)
- Fostriecin: chemistry and biology. Lewy, D.S., Gauss, C.M., Soenen, D.R., Boger, D.L. Current medicinal chemistry. (2002)
- Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Hartman, N.R., Yarchoan, R., Pluda, J.M., Thomas, R.V., Marczyk, K.S., Broder, S., Johns, D.G. Clin. Pharmacol. Ther. (1990)
- Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272. Wang, Y.X., Freedberg, D.I., Yamazaki, T., Wingfield, P.T., Stahl, S.J., Kaufman, J.D., Kiso, Y., Torchia, D.A. Biochemistry (1996)
- Recent developments in the field of tumor-inhibiting metal complexes. Galanski, M., Arion, V.B., Jakupec, M.A., Keppler, B.K. Curr. Pharm. Des. (2003)
- Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo. Burger, A.M., Hartung, G., Stehle, G., Sinn, H., Fiebig, H.H. Int. J. Cancer (2001)
- Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation. Honore, S., Kamath, K., Braguer, D., Wilson, L., Briand, C., Jordan, M.A. Mol. Cancer Ther. (2003)
- Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. Honore, S., Kamath, K., Braguer, D., Horwitz, S.B., Wilson, L., Briand, C., Jordan, M.A. Cancer Res. (2004)
- Sensitizers and protectors in radiotherapy. Brown, J.M. Cancer (1985)
- Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. Baselga, J., Pfister, D., Cooper, M.R., Cohen, R., Burtness, B., Bos, M., D'Andrea, G., Seidman, A., Norton, L., Gunnett, K., Falcey, J., Anderson, V., Waksal, H., Mendelsohn, J. J. Clin. Oncol. (2000)
- Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J.M., Herbst, R., LoRusso, P., Rischin, D., Sauleda, S., Gee, J., Nicholson, R.I., Baselga, J. J. Clin. Oncol. (2002)
- Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Dorie, M.J., Brown, J.M. Cancer Res. (1993)
- Phase I and clinical pharmacological evaluation of a parenteral hexamethylmelamine formulation. Ames, M.M., Richardson, R.L., Kovach, J.S., Moertel, C.G., O'Connell, M.J. Cancer Res. (1990)
- CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Hjarnaa, P.J., Jonsson, E., Latini, S., Dhar, S., Larsson, R., Bramm, E., Skov, T., Binderup, L. Cancer Res. (1999)
- In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Lotze, M.T., Custer, M.C., Sharrow, S.O., Rubin, L.A., Nelson, D.L., Rosenberg, S.A. Cancer Res. (1987)
- P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Sandor, V., Senderowicz, A., Mertins, S., Sackett, D., Sausville, E., Blagosklonny, M.V., Bates, S.E. Br. J. Cancer (2000)
- Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis. Juarez, J., Bendall, L., Bradstock, K. Curr. Pharm. Des. (2004)
- FLT3 and its role in the pathogenesis of acute myeloid leukaemia. Reilly, J.T. Leuk. Lymphoma (2003)
- Gene therapy of ovarian cancer. Bauknecht, T., Meinhold-Heerlein, I. Current women's health reports. (2002)
- Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Amit-Vazina, M., Shishodia, S., Harris, D., Van, Q., Wang, M., Weber, D., Alexanian, R., Talpaz, M., Aggarwal, B.B., Estrov, Z. Br. J. Cancer (2005)
- Alterations in oxygen transport following WR-2721. Glover, D., Negendank, W., Delivoria-Papadopoulos, M., Glick, J.H. Int. J. Radiat. Oncol. Biol. Phys. (1984)
- Inhibition of induced angiogenesis in a human microvascular endothelial cell line by ET-18-OCH3. Candal, F.J., Bosse, D.C., Vogler, W.R., Ades, E.W. Cancer Chemother. Pharmacol. (1994)
- Pharmaceutical development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent EO9. Jonkman-de Vries, J.D., Talsma, H., Henrar, R.E., Kettenes-van den Bosch, J.J., Bult, A., Beijnen, J.H. Cancer Chemother. Pharmacol. (1994)
- Clinical trial and pharmacokinetics of carboplatin 560 mg/m2 in children. Doz, F., Brugières, L., Bastian, G., Quintana, E., Lemerle, J., Zucker, J.M. Med. Pediatr. Oncol. (1990)